Abstract
BackgroundThe occurrence of depression in patients with schizophrenia (PWS) increases the risk of relapse, frequency and duration of hospitalisation, and decreases social and occupational functioning.ObjectiveThis study aimed to assess prevalence of unrecognised comorbid depression and its determinants in PWS.MethodA cross-sectional study was conducted from 1 to 30 March 2019 at Amanuel mental specialized hospital among 300 PWS. The 9-item Calgary Depression Scale for Schizophrenia was used to assess comorbid depression. Logistic regression was used to determine the association between outcome and explanatory variables. Statistical significance was declared at p value <0.05 with 95% CI.ResultsThe prevalence of unrecognised comorbid depression was found to be 30.3%. Living alone (adjusted OR (AOR)=3.49, 95% CI=0.45 to 8.36), having poor (AOR=4.43, 95% CI=1.45 to 13.58) and moderate (AOR=4.45, 95% CI=1.30 to 15.22) social support, non-adherence to medication (AOR=3.82, 95% CI=1.70 to 8.55), presenting with current negative symptoms such as asocialia (AOR=4.33, 95% CI=1.98 to 9.45) and loss of personal motivation (AOR=3.46, 95% CI=1.53 to 7.84), and having suicidal behaviour (AOR=6.83, 95% CI=3.24 to 14.41) were the significant predictors of comorbid depression in PWS.ConclusionThis study revealed considerably a high prevalence of unrecognised comorbid depression among PWS. Therefore, clinicians consider timely screening and treating of comorbid depression in PWS.
Reference50 articles.
1. World Health Organization . World Health organization. the global burden of disease: 2004 update. Geneva: World Health Organization, 2008.
2. The societal cost of schizophrenia in Sweden;Ekman;J Ment Health Policy Econ,2013
3. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010
4. Psychiatric Comorbidities and Schizophrenia
5. Siris SG BC . Depression and schizophrenia. 2nd ed. Hirsch SR WD, editor. Oxford, UK: Blackwell Publishing Ltd, 2003.